Company earnings

ADGM Earnings Date & History

Adagio Medical Holdings Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.

Last updated Aug 19, 2026 at 4:08 PM ET

Adagio Medical Holdings Inc

Health Care

Next earnings date
Wednesday, August 19, 2026
Reporting session
Time TBD
EPS estimate
$-0.31
Revenue estimate
$0

ADGM earnings history

Report dateQuarterEPS est.EPS actualSurpriseRevenue
Tuesday, May 12, 2026Q1 2026$-0.30$-0.31-4.3%$0
Friday, March 27, 2026Q4 2025$-0.32$-0.16+49.4%$0

What the market is watching in ADGM's next report

  • The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
  • Ticker Read combines trend, relative strength and catalysts in one research view.
  • Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Free by email

Get the week's earnings by email

One free email each week: the reports that matter, when they land, and what the market is watching.

No account required. Unsubscribe any time. Research and education only — not investment advice.

Frequently asked questions

When is the next ADGM earnings date?
Adagio Medical Holdings Inc is scheduled to report on Wednesday, August 19, 2026 (Time TBD). Dates can change until the company confirms them.
Does ADGM report before or after the market?
The next report is scheduled time tbd.
What EPS is expected for ADGM?
Consensus EPS for the upcoming quarter is $-0.31, on revenue of $0.

Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.

ADGM earnings discussion

Anyone can read. Any free Hyper Stocks account can join in.

Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.

Loading discussion…

Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.